Zebra Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Zebra Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,382	Closed	-$80K	–	86
2022 Q2	$80K	Sell	11,382 -263	-2%	-$1.93K	0.24%	91
2022 Q1	$97K	Sell	11,645 -5,848	-33%	-$41.3K	0.22%	110
2021 Q4	$118K	Sell	17,493 -6,449	-27%	-$42.4K	0.19%	141
2021 Q3	$127K	Sell	23,942 -23,152	-49%	-$127K	0.15%	167
2021 Q2	$271K	Sell	47,094 -5,087	-10%	-$26.3K	0.32%	114
2021 Q1	$241K	Buy	+52,181	New	+$207K	0.27%	126
2020 Q3	–	Sell	-44,664	Closed	-$206K	–	180
2020 Q2	$206K	Sell	44,664 -1,010	-2%	-$4.54K	0.3%	157
2020 Q1	$176K	Sell	45,674 -368	-0.8%	-$1.51K	0.28%	155
2019 Q4	$173K	Buy	+46,042	New	+$215K	0.15%	241

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zebra Capital Management's CPRX Position: Q3 2022 in Review

Zebra Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2022, closing a stake of 11,382 shares — an estimated $80K sold.

Zebra Capital Management first reported a position in CPRX in Q4 2019 and held it in 9 quarters. The position peaked at $271K in Q2 2021. 229 funds tracked by Wall St. Rank hold CPRX as of Q3 2022.

Zebra Capital Management reported no remaining Catalyst Pharmaceutical position as of Q3 2022 after selling out during the quarter.
Zebra Capital Management sold 11,382 Catalyst Pharmaceutical shares in Q3 2022, an estimated $80K.
Zebra Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2019 and held it in 9 quarters.
Zebra Capital Management's Catalyst Pharmaceutical position peaked at $271K in Q2 2021.
229 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2022.

Based on Zebra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.